Effect of two 5-HT6 receptor antagonists on the rat liver: A molecular approach

Pharmacogenomics Journal

Volumn 3, Issue 6, 2003, Pages 320-334

  Suter, Laura ^a   Haiker, M ^a   de Vera, M C ^a   Albertini, S ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

5 HT6 receptor antagonist; CYP P450; Drug metabolizing enzymes; Liver; Steatosis; Toxicogenomics

Indexed keywords

4 (2 BROMO 6 PYRROLIDIN 1 YLPYRIDINE 4 SULFONYL)PHENYLAMINE; 4 AMINO N (6 BROMO 1H INDOL 4 YL)BENZENESULFONAMIDE; ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 2B; G PROTEIN COUPLED RECEPTOR; LACTATE DEHYDROGENASE; RO 65 7199; RO 66 0074; SEROTONIN; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; STEROL; UNCLASSIFIED DRUG; 8 ACENAPHTHEN 1 YL 1 PHENYL 1,3,8 TRIAZASPIRO(4.5)DECAN 4 ONE; 8-ACENAPHTHEN-1-YL-1-PHENYL-1,3,8-TRIAZASPIRO(4.5)DECAN-4-ONE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; RO 65-7199; RO 66-0074; SEROTONIN RECEPTOR; SPIRO COMPOUND; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; FATTY LIVER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC TOXICOLOGY; LIPID STORAGE; LIVER; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; RAT; STEROL METABOLISM; UNINDEXED SEQUENCE; ANIMAL; CHEMISTRY; DRUG EFFECT; GENETICS; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALIA;

ANIMALS; GENE EXPRESSION PROFILING; IMIDAZOLES; INDOLES; LIVER; MALE; PYRIDINES; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SPIRO COMPOUNDS; SULFONAMIDES;

EID: 0347287023     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500207     Document Type: Article

References (34)

1. Mossner R, Schmitt A, Syagailo Y, Gerlach M, Riederer P, Lesch KP. The serotonin transporter in Alzheimer's and Parkinson's disease. J Neural Transm Suppl 2000; 60: 345-350.
2. Saudou F, Hen R. 5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates. Neurochem Int 1994; 25: 503-532.
3. Ruat M, Traiffort E, Arrang JM, Tardivel-Lacombe J, Diaz J, Leurs R et al. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 1993; 193: 268-276.
4. Yoshioka M, Matsumoto M, Togashi H, Mori K, Saito H. Central distribution and function of 5-HT6 receptor subtype in the rat brain. Life Sci 1998; 62: 1473-1477.
5. Sleight AJ, Monsma Jr FJ, Borroni E, Austin RH, Bourson A. Effects of altered 5-ht6 expression in the rat: functional studies using antisense oligonucleotides. Behav Brain Res 1996; 73: 245-248.
6. Bourson A, Borroni E, Austin RH, Monsma Jr FJ, Sleight AJ. Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmacol Exp Ther 1995; 274: 173-180.
7. Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC. A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001; 41: 210-219.
8. Pennie WD, Kimber I. Toxicogenomics; transcript profiling and potential application to chemical allergy. Toxicol In Vitro 2002; 16: 319-326.
9. Simmons PT, Fortier CJ. Toxicogenomics: the new frontier in risk analysis. Carcinogenesis 2002; 23: 903-905.
10. Marchant GE. Toxicogenomics and toxic torts. Trends Biotechnol 2002; 20: 329-332.
11. Novatchkova M, Eisenhaber F. Can molecular mechanisms of biological processes be extracted from expression profiles? Case study: endothelial contribution to tumor-induced angiogenesis. BioEssays 2001; 23: 1159-1175.
12. de Longueville F, Surry D, Meneses-Lorente G, Bertholet V, Talbot V, Evrard S et al. Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray. Biochem Pharmacol 2002; 64: 137-149.
13. Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol Lett 2001; 120: 359-368.
14. Bulera SJ, Eddy SM, Ferguson E, Jatkoe TA, Reindel JF, Bleavins MR et al. RNA expression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays. Hepatology 2001; 33: 1239-1258.
15. Hamadeh HK, Bushel PR, Jayadev S, DiSorbo O, Bennett L, Li L et al. Prediction of compound signature using high density gene expression profiling. Toxicol Sci 2002; 67: 232-240.
16. Fountoulakis M, de Vera M, Crameri F, Boess F, Gasser R, Albertini S et al. Modulation of gene and protein expression by carbon tetrachloride in the rat liver. Toxicol Appl Pharmacol 2002; 183: 71.
17. Lian Z, Kluger Y, Greenbaum DS, Tuck D, Gerstein M, Berliner N et al. Genomic and proteomic analysis of the myeloid differentiation program: global analysis of gene expression during induced differentiation in the MPRO cell line. Blood 2002; 100: 3209-3220.
18. Whysner J, Ross PM, Williams GM. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol Ther 1996; 71: 153-191.
19. Omiecinski CJ, Hassett C, Costa P. Developmental expression and in situ localization of the phenobarbital-inducible rat hepatic mRNAs for cytochromes CYP2B1, CYP2B2, CYP2C6, and CYP3A1. Mol Pharmacol 1990; 38: 462-470.
20. Hoen PA, Bijsterbosch MK, van Berkel TJ, Vermeulen NP, Commandeur JN. Midazolam is a phenobarbital-like cytochrome P450 inducer in rats. J Pharmacol Exp Ther 2001; 299: 921-927.
21. Waxman DJ, Walsh C. Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: purification, characterization, and interactions with metyrapone and cytochrome b5. Biochemistry 1983; 22: 4846-4855.
22. Nakayama K, Suwa Y, Mizukami Y, Sogawa K, Fujii-Kuriyama Y. Cloning and sequencing of a novel rat cytochrome P450 2B-encoding gene. Gene 1993; 136: 333-336.
23. Suwa Y, Mizukami Y, Sogawa K, Fujii-Kuriyama Y. Gene structure of a major form of phenobarbital-inducible cytochrome P- 450 in rat liver. J Biol Chem 1985; 260: 7980-7984.
24. Agrawal AK, Shapiro BH. Phenobarbital induction of hepatic CYP2B1 and CYP2B2: pretranscriptional and post-transcriptional effects of gender, adult age, and phenobarbital dose. Mol Pharmacol 1996; 49: 523-531.
25. Kawamoto T, Kakizaki S, Yoshinari K, Negishi M. Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b1O gene. Mol Endocrinol 2000; 14: 1897-1905.
26. George DK, Crawford DH. Anti bacterial-induced hepatotoxicity. Incidence, prevention and management. Drug Saf 1996; 15: 79-85.
27. Ourlin JC, Handschin C, Kaufmann M, Meyer UA. A link between cholesterol levels and phenobarbital induction of cytochromes P450. Biochem Biophys Res Commun 2002; 291: 378-384.
28. Kocarek TA, Kraniak JM, Reddy AB. Regulation of rat hepatic cytochrome P450 expression by sterol biosynthesis inhibition: inhibitors of squalene synthase are potent inducers of CYP2B expression in primary cultured rat hepatocytes and rat liver. Mol Pharmacol 1998; 54: 474-484.
29. Yamada H, Matsuki Y, Yamaguchi T, Oguri K. Effect of a ligand selective for peripheral benzodiazepine receptors on the expression of rat hepatic P-450 cytochromes: assessment of the effect in vivo and in a hepatocyte culture system. Drug Metab Dispos 1999; 27: 1242-1247.
30. Guo GL, Lambert G, Negishi M, Ward JM, Brewer Jr HB, Kliewer SA et al. Complementary roles of Farnesoid X receptor, pregnane X receptor, and constitutive Androstane receptor in protection against bile acid toxicity. J Biol Chem 2003.
31. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000; 347(Part 2): 321-337.
32. Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998; 28: 410-416.
33. Akiyama TE, Ward JM, Gonzalez FJ. Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1 alpha (HNF1 alpha). Alterations in fatty acid homeostasis in HNF1 alpha-deficient mice. J Biol Chem 2000; 275: 27117-27122.
34. Freneaux E, Labbe G, Letteron P, The Le D, Degott C, Geneve J et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988; 8: 1056-1062.